Questions discussed in this category
How is this entity distinct from other secondary HLH entities?
Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?
20973192521733317088177391618613957128731269891687034
Papers discussed in this category
Blood, 2020 Sep 23
J Clin Oncol, 2021 Dec 9
Blood Cancer Discov, 2021 Dec 01
Exp Hematol Oncol, 2021 Feb 19
Blood Adv,
Radiother Oncol, 2021 Dec 7
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Int J Radiat Oncol Biol Phys, 2022 Dec 20
Transplant Cell Ther, 2022 Dec 30
Blood advances, 2020 Jul 28
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26
Blood advances, 2020 Nov 24
J Hematol Oncol, 2022 Mar 26
Blood advances, 2022 May 10